Close Menu

This story has been updated from a previous version to include information about JP Morgan initiating coverage of Adaptive Biotechnologies.

NEW YORK – Cowen and William Blair today initiated coverage of Adaptive Biotechnologies, both with Outperform ratings.

JP Morgan also initiated coverage with an Overweight rating and provided a price target of $45 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.